Issue: May 2019
May 07, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
CLEAR Wisdom
Issue: May 2019
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Assessment of bempedoic acid (Esperion Therapeutics) vs. placebo for LDL reduction in high-risk statin-treated patients.